Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25029416 | 0.93 | CRBN (0.38) | CRBNDDB1OPRM1OPRL1OPRK1 | |
| SCHEMBL30981567 | 0.91 | CRBN (0.38) | CRBNDDB1IKZF2POLB | |
| SCHEMBL25031304 | 0.88 | CRBN (0.38) | CRBNDDB1 | |
| SCHEMBL30479076 | 0.88 | CRBN (0.38) | CRBNDDB1 | |
| SCHEMBL30965602 | 0.86 | CRBN (0.38) | CRBNDDB1OPRM1OPRL1OPRK1 | |
| SCHEMBL25823260 | 0.83 | CRBN (0.40) | CRBNDDB1POLB | |
| SCHEMBL25335977 | 0.83 | IKZF2 (0.36) | CRBNDDB1IKZF2 | |
| SCHEMBL30475498 | 0.83 | CRBN (0.38) | CRBNDDB1OPRM1OPRL1OPRK1 | |
| SCHEMBL25031328 | 0.83 | CRBN (0.38) | CRBNDDB1OPRM1OPRL1OPRK1 | |
| SCHEMBL25031065 | 0.81 | ESR1 (0.42) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024155112-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | UPPTHERA, INC. (KR) | 2024-07-25 | — | — | WO | disclosed |
| CN-116261458-B | PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-11939334-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-03-26 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| EP-4157850-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023018236-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018236-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939334-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | CRBN 2496/4885DDB1 77/4885OPRM1 4655/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885OPRM1 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.